Grimes & Company, Inc. Novo Nordisk A S Transaction History

Grimes & Company, Inc.

  • $3.66 Billion
  • Q3 2024

A detailed history of Grimes & Company, Inc. transactions in Novo Nordisk A S stock. As of the latest transaction made, Grimes & Company, Inc. holds 105,941 shares of NVO stock, worth $9.26 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
105,941
Previous 107,241 1.21%
Holding current value
$9.26 Million
Previous $15.3 Million 17.59%
% of portfolio
0.35%
Previous 0.46%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024
SELL
$119.07 - $145.42 $154,791 - $189,045
-1,300 Reduced 1.21%
105,941 $12.6 Million
Q2 2024

Jul 22, 2024
BUY
$122.71 - $146.91 $191,059 - $228,738
1,557 Added 1.47%
107,241 $15.3 Million
Q1 2024

Apr 17, 2024
BUY
$102.11 - $135.92 $297,548 - $396,070
2,914 Added 2.84%
105,684 $13.6 Million
Q4 2023

Jan 24, 2024
BUY
$87.78 - $105.45 $165,816 - $199,195
1,889 Added 1.87%
102,770 $10.6 Million
Q3 2023

Oct 19, 2023
BUY
$90.94 - $199.54 $4.31 Million - $9.46 Million
47,395 Added 88.61%
100,881 $9.17 Million
Q2 2023

Jul 19, 2023
BUY
$155.98 - $172.65 $38,995 - $43,162
250 Added 0.47%
53,486 $8.66 Million
Q1 2023

Apr 20, 2023
SELL
$132.34 - $159.14 $3.5 Million - $4.21 Million
-26,426 Reduced 33.17%
53,236 $8.47 Million
Q4 2022

Jan 25, 2023
BUY
$102.55 - $135.33 $119,983 - $158,336
1,170 Added 1.49%
79,662 $0
Q3 2022

Oct 28, 2022
SELL
$95.28 - $116.93 $147,969 - $181,592
-1,553 Reduced 1.94%
78,492 $7.82 Million
Q2 2022

Jul 22, 2022
SELL
$103.24 - $121.81 $3.09 Million - $3.65 Million
-29,925 Reduced 27.21%
80,045 $8.92 Million
Q1 2022

May 06, 2022
SELL
$93.1 - $112.54 $6.32 Million - $7.64 Million
-67,853 Reduced 38.16%
109,970 $12.2 Million
Q4 2021

Feb 01, 2022
SELL
$95.88 - $117.08 $59,829 - $73,057
-624 Reduced 0.35%
177,823 $19.9 Million
Q3 2021

Nov 08, 2021
SELL
$84.42 - $106.62 $313,367 - $395,773
-3,712 Reduced 2.04%
178,447 $17.1 Million
Q2 2021

Aug 04, 2021
BUY
$67.66 - $84.76 $48,309 - $60,518
714 Added 0.39%
182,159 $15.3 Million
Q1 2021

May 12, 2021
BUY
$67.06 - $75.82 $1.37 Million - $1.55 Million
20,418 Added 12.68%
181,445 $12.2 Million
Q4 2020

Feb 02, 2021
BUY
$63.89 - $73.8 $504,794 - $583,093
7,901 Added 5.16%
161,027 $11.2 Million
Q3 2020

Nov 12, 2020
SELL
$63.69 - $70.22 $2.89 Million - $3.18 Million
-45,350 Reduced 22.85%
153,126 $10.6 Million
Q2 2020

Jul 31, 2020
SELL
$58.54 - $67.94 $260,444 - $302,265
-4,449 Reduced 2.19%
198,476 $13 Million
Q1 2020

May 05, 2020
SELL
$49.46 - $64.78 $305,761 - $400,469
-6,182 Reduced 2.96%
202,925 $12.2 Million
Q4 2019

Feb 05, 2020
SELL
$49.86 - $58.26 $241,471 - $282,153
-4,843 Reduced 2.26%
209,107 $12.1 Million
Q3 2019

Nov 05, 2019
BUY
$47.54 - $53.43 $75,350 - $84,686
1,585 Added 0.75%
213,950 $11.1 Million
Q2 2019

Jul 30, 2019
BUY
$46.79 - $52.47 $126,941 - $142,351
2,713 Added 1.29%
212,365 $10.8 Million
Q1 2019

May 02, 2019
BUY
$46.36 - $52.63 $204,354 - $231,993
4,408 Added 2.15%
209,652 $11 Million
Q4 2018

Feb 01, 2019
BUY
$41.54 - $47.25 $23,387 - $26,601
563 Added 0.28%
205,244 $9.46 Million
Q3 2018

Nov 09, 2018
BUY
$46.76 - $51.24 $379,691 - $416,068
8,120 Added 4.13%
204,681 $9.65 Million
Q2 2018

Aug 10, 2018
SELL
$44.29 - $50.42 $88,004 - $100,184
-1,987 Reduced 1.0%
196,561 $9.07 Million
Q1 2018

May 07, 2018
SELL
$48.49 - $58.14 $7,418 - $8,895
-153 Reduced 0.08%
198,548 $9.78 Million
Q4 2017

Feb 05, 2018
SELL
$47.53 - $53.73 $194,160 - $219,487
-4,085 Reduced 2.01%
198,701 $10.7 Million
Q3 2017

Nov 03, 2017
BUY
$41.15 - $49.22 $8.34 Million - $9.98 Million
202,786
202,786 $9.76 Million

Others Institutions Holding NVO

# of Institutions
1,957
Shares Held
320M
Call Options Held
5.49M
Put Options Held
7.78M
View Full List

About NOVO NORDISK A S

NVO Quotes by TradingView
  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Grimes & Company, Inc. Portfolio

Follow Grimes & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Grimes & Company, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email